Ontology type: schema:ScholarlyArticle Open Access: True
2016-09-22
AUTHORSTsuyoshi Nozue, Hiroaki Hattori, Kazuyuki Ogawa, Takeshi Kujiraoka, Tadao Iwasaki, Tsutomu Hirano, Ichiro Michishita
ABSTRACTBackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311. More... »
PAGES165
http://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8
DOIhttp://dx.doi.org/10.1186/s12944-016-0339-8
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1046753598
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/27658826
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical Biochemistry and Metabolomics",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.417368.f",
"name": [
"Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Nozue",
"givenName": "Tsuyoshi",
"id": "sg:person.01033145125.12",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan",
"id": "http://www.grid.ac/institutes/grid.410848.1",
"name": [
"Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
],
"type": "Organization"
},
"familyName": "Hattori",
"givenName": "Hiroaki",
"id": "sg:person.01306227053.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan",
"id": "http://www.grid.ac/institutes/grid.410848.1",
"name": [
"Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
],
"type": "Organization"
},
"familyName": "Ogawa",
"givenName": "Kazuyuki",
"id": "sg:person.01022006542.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan",
"id": "http://www.grid.ac/institutes/grid.410848.1",
"name": [
"Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
],
"type": "Organization"
},
"familyName": "Kujiraoka",
"givenName": "Takeshi",
"id": "sg:person.01130141300.55",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan",
"id": "http://www.grid.ac/institutes/grid.410848.1",
"name": [
"Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan"
],
"type": "Organization"
},
"familyName": "Iwasaki",
"givenName": "Tadao",
"id": "sg:person.0751577337.13",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.410714.7",
"name": [
"Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Hirano",
"givenName": "Tsutomu",
"id": "sg:person.016274235662.39",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan",
"id": "http://www.grid.ac/institutes/grid.417368.f",
"name": [
"Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan"
],
"type": "Organization"
},
"familyName": "Michishita",
"givenName": "Ichiro",
"id": "sg:person.0732262025.70",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s40618-016-0433-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1052469678",
"https://doi.org/10.1007/s40618-016-0433-9"
],
"type": "CreativeWork"
}
],
"datePublished": "2016-09-22",
"datePublishedReg": "2016-09-22",
"description": "BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r\u2009=\u20090.195, p\u2009=\u20090.05); small, dense LDL (r\u2009=\u20090.336, p\u2009=\u20090.0006); and oxidized LDL (r\u2009=\u20090.268, p\u2009=\u20090.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (\u03b2\u2009=\u20090.235, p\u2009=\u20090.01); small, dense LDL (\u03b2\u2009=\u20090.143, p\u2009=\u20090.03); and oxidized LDL (\u03b2\u2009=\u20090.268, p\u2009=\u20090.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311.",
"genre": "article",
"id": "sg:pub.10.1186/s12944-016-0339-8",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1031029",
"issn": [
"1476-511X"
],
"name": "Lipids in Health and Disease",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "15"
}
],
"keywords": [
"proprotein convertase subtilisin/kexin type 9",
"coronary artery disease",
"convertase subtilisin/kexin type 9",
"subtilisin/kexin type 9",
"serum levels",
"dense LDL",
"artery disease",
"PCSK9 levels",
"atherogenic lipoproteins",
"serum low-density lipoprotein cholesterol levels",
"type 9",
"low-density lipoprotein cholesterol levels",
"serum proprotein convertase subtilisin/kexin type 9",
"lipid-lowering therapy",
"metabolic risk factors",
"lipoprotein cholesterol levels",
"Clinical Trials Registry",
"body mass index",
"levels of triglycerides",
"multivariate regression analysis",
"atherosclerotic status",
"MethodsSerum levels",
"Trials Registry",
"mass index",
"cholesterol levels",
"risk factors",
"apolipoprotein B",
"patients",
"LDL",
"lipoprotein",
"significant predictors",
"regression analysis",
"disease",
"key regulator",
"levels",
"registry",
"therapy",
"triglycerides",
"insulin",
"trials",
"predictors",
"glucose",
"correlation",
"status",
"index",
"factors",
"study",
"role",
"regulator",
"purpose",
"analysis",
"ID",
"interaction"
],
"name": "Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease",
"pagination": "165",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1046753598"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12944-016-0339-8"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"27658826"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12944-016-0339-8",
"https://app.dimensions.ai/details/publication/pub.1046753598"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:17",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_700.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12944-016-0339-8"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12944-016-0339-8'
This table displays all metadata directly associated to this object as RDF triples.
166 TRIPLES
22 PREDICATES
80 URIs
71 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s12944-016-0339-8 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1101 |
3 | ″ | schema:author | N76e1037a55314945807913066a84e633 |
4 | ″ | schema:citation | sg:pub.10.1007/s40618-016-0433-9 |
5 | ″ | schema:datePublished | 2016-09-22 |
6 | ″ | schema:datePublishedReg | 2016-09-22 |
7 | ″ | schema:description | BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum low-density lipoprotein (LDL) cholesterol levels. Recently, PCSK9 has additionally been related to metabolic risk factors such as the levels of triglycerides, apolipoprotein B (apoB), insulin, and glucose, as well as body mass index. The purpose of this study was to investigate correlations between serum levels of PCSK9 and apoB-containing atherogenic lipoproteins in patients with coronary artery disease (CAD).MethodsSerum levels of PCSK9 and lipoprotein(a) [Lp(a)]; small, dense LDL; and oxidized LDL were measured in 101 patients with CAD who were not receiving lipid-lowering therapy.ResultsSerum hetero-dimer PCSK9 levels were positively correlated with serum levels of Lp(a) (r = 0.195, p = 0.05); small, dense LDL (r = 0.336, p = 0.0006); and oxidized LDL (r = 0.268, p = 0.008). Multivariate regression analyses showed that serum hetero-dimer PCSK9 was a significant predictor of serum levels of Lp(a) (β = 0.235, p = 0.01); small, dense LDL (β = 0.143, p = 0.03); and oxidized LDL (β = 0.268, p = 0.008).ConclusionsSerum PCSK9 levels were positively correlated with serum levels of Lp(a); small, dense LDL; and oxidized LDL in patients with CAD. This suggests that the interaction between serum PCSK9 and apoB-containing lipoproteins plays a role in establishing the atherosclerotic status of patients.Trial registrationUMIN Clinical Trials Registry, UMIN ID: C000000311. |
8 | ″ | schema:genre | article |
9 | ″ | schema:inLanguage | en |
10 | ″ | schema:isAccessibleForFree | true |
11 | ″ | schema:isPartOf | N6e11c5764dac42f7a9e6088e54e1ee62 |
12 | ″ | ″ | Nb4839c368492474f9faf1b641c43dcf9 |
13 | ″ | ″ | sg:journal.1031029 |
14 | ″ | schema:keywords | Clinical Trials Registry |
15 | ″ | ″ | ID |
16 | ″ | ″ | LDL |
17 | ″ | ″ | MethodsSerum levels |
18 | ″ | ″ | PCSK9 levels |
19 | ″ | ″ | Trials Registry |
20 | ″ | ″ | analysis |
21 | ″ | ″ | apolipoprotein B |
22 | ″ | ″ | artery disease |
23 | ″ | ″ | atherogenic lipoproteins |
24 | ″ | ″ | atherosclerotic status |
25 | ″ | ″ | body mass index |
26 | ″ | ″ | cholesterol levels |
27 | ″ | ″ | convertase subtilisin/kexin type 9 |
28 | ″ | ″ | coronary artery disease |
29 | ″ | ″ | correlation |
30 | ″ | ″ | dense LDL |
31 | ″ | ″ | disease |
32 | ″ | ″ | factors |
33 | ″ | ″ | glucose |
34 | ″ | ″ | index |
35 | ″ | ″ | insulin |
36 | ″ | ″ | interaction |
37 | ″ | ″ | key regulator |
38 | ″ | ″ | levels |
39 | ″ | ″ | levels of triglycerides |
40 | ″ | ″ | lipid-lowering therapy |
41 | ″ | ″ | lipoprotein |
42 | ″ | ″ | lipoprotein cholesterol levels |
43 | ″ | ″ | low-density lipoprotein cholesterol levels |
44 | ″ | ″ | mass index |
45 | ″ | ″ | metabolic risk factors |
46 | ″ | ″ | multivariate regression analysis |
47 | ″ | ″ | patients |
48 | ″ | ″ | predictors |
49 | ″ | ″ | proprotein convertase subtilisin/kexin type 9 |
50 | ″ | ″ | purpose |
51 | ″ | ″ | registry |
52 | ″ | ″ | regression analysis |
53 | ″ | ″ | regulator |
54 | ″ | ″ | risk factors |
55 | ″ | ″ | role |
56 | ″ | ″ | serum levels |
57 | ″ | ″ | serum low-density lipoprotein cholesterol levels |
58 | ″ | ″ | serum proprotein convertase subtilisin/kexin type 9 |
59 | ″ | ″ | significant predictors |
60 | ″ | ″ | status |
61 | ″ | ″ | study |
62 | ″ | ″ | subtilisin/kexin type 9 |
63 | ″ | ″ | therapy |
64 | ″ | ″ | trials |
65 | ″ | ″ | triglycerides |
66 | ″ | ″ | type 9 |
67 | ″ | schema:name | Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease |
68 | ″ | schema:pagination | 165 |
69 | ″ | schema:productId | N05c59aa88e8a45b4b13d0b4ae6322558 |
70 | ″ | ″ | N108920e109fa466d84de33efbc8d5e5a |
71 | ″ | ″ | N6cfec691317343d4a84619a8b6f9d7e2 |
72 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1046753598 |
73 | ″ | ″ | https://doi.org/10.1186/s12944-016-0339-8 |
74 | ″ | schema:sdDatePublished | 2022-06-01T22:17 |
75 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
76 | ″ | schema:sdPublisher | N9c800c470f2847cd833715b9fe39e8c8 |
77 | ″ | schema:url | https://doi.org/10.1186/s12944-016-0339-8 |
78 | ″ | sgo:license | sg:explorer/license/ |
79 | ″ | sgo:sdDataset | articles |
80 | ″ | rdf:type | schema:ScholarlyArticle |
81 | N05c59aa88e8a45b4b13d0b4ae6322558 | schema:name | pubmed_id |
82 | ″ | schema:value | 27658826 |
83 | ″ | rdf:type | schema:PropertyValue |
84 | N108920e109fa466d84de33efbc8d5e5a | schema:name | doi |
85 | ″ | schema:value | 10.1186/s12944-016-0339-8 |
86 | ″ | rdf:type | schema:PropertyValue |
87 | N2c97f8b18ad84cd0ab234c48d9eeb023 | rdf:first | sg:person.0732262025.70 |
88 | ″ | rdf:rest | rdf:nil |
89 | N3e3bf91fee5841a08efa35ea6c42da74 | rdf:first | sg:person.0751577337.13 |
90 | ″ | rdf:rest | N86b6cacb0ef64f5abfbdfea6d623f59f |
91 | N48f21151931240bda652ef9c9055888a | rdf:first | sg:person.01306227053.48 |
92 | ″ | rdf:rest | N4a4473e0a1844e1895cb73e028e55938 |
93 | N4a4473e0a1844e1895cb73e028e55938 | rdf:first | sg:person.01022006542.43 |
94 | ″ | rdf:rest | N740ba76ac76046fe94b90cb4310a70e9 |
95 | N6cfec691317343d4a84619a8b6f9d7e2 | schema:name | dimensions_id |
96 | ″ | schema:value | pub.1046753598 |
97 | ″ | rdf:type | schema:PropertyValue |
98 | N6e11c5764dac42f7a9e6088e54e1ee62 | schema:issueNumber | 1 |
99 | ″ | rdf:type | schema:PublicationIssue |
100 | N740ba76ac76046fe94b90cb4310a70e9 | rdf:first | sg:person.01130141300.55 |
101 | ″ | rdf:rest | N3e3bf91fee5841a08efa35ea6c42da74 |
102 | N76e1037a55314945807913066a84e633 | rdf:first | sg:person.01033145125.12 |
103 | ″ | rdf:rest | N48f21151931240bda652ef9c9055888a |
104 | N86b6cacb0ef64f5abfbdfea6d623f59f | rdf:first | sg:person.016274235662.39 |
105 | ″ | rdf:rest | N2c97f8b18ad84cd0ab234c48d9eeb023 |
106 | N9c800c470f2847cd833715b9fe39e8c8 | schema:name | Springer Nature - SN SciGraph project |
107 | ″ | rdf:type | schema:Organization |
108 | Nb4839c368492474f9faf1b641c43dcf9 | schema:volumeNumber | 15 |
109 | ″ | rdf:type | schema:PublicationVolume |
110 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
111 | ″ | schema:name | Medical and Health Sciences |
112 | ″ | rdf:type | schema:DefinedTerm |
113 | anzsrc-for:1101 | schema:inDefinedTermSet | anzsrc-for: |
114 | ″ | schema:name | Medical Biochemistry and Metabolomics |
115 | ″ | rdf:type | schema:DefinedTerm |
116 | sg:journal.1031029 | schema:issn | 1476-511X |
117 | ″ | schema:name | Lipids in Health and Disease |
118 | ″ | schema:publisher | Springer Nature |
119 | ″ | rdf:type | schema:Periodical |
120 | sg:person.01022006542.43 | schema:affiliation | grid-institutes:grid.410848.1 |
121 | ″ | schema:familyName | Ogawa |
122 | ″ | schema:givenName | Kazuyuki |
123 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022006542.43 |
124 | ″ | rdf:type | schema:Person |
125 | sg:person.01033145125.12 | schema:affiliation | grid-institutes:grid.417368.f |
126 | ″ | schema:familyName | Nozue |
127 | ″ | schema:givenName | Tsuyoshi |
128 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033145125.12 |
129 | ″ | rdf:type | schema:Person |
130 | sg:person.01130141300.55 | schema:affiliation | grid-institutes:grid.410848.1 |
131 | ″ | schema:familyName | Kujiraoka |
132 | ″ | schema:givenName | Takeshi |
133 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130141300.55 |
134 | ″ | rdf:type | schema:Person |
135 | sg:person.01306227053.48 | schema:affiliation | grid-institutes:grid.410848.1 |
136 | ″ | schema:familyName | Hattori |
137 | ″ | schema:givenName | Hiroaki |
138 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306227053.48 |
139 | ″ | rdf:type | schema:Person |
140 | sg:person.016274235662.39 | schema:affiliation | grid-institutes:grid.410714.7 |
141 | ″ | schema:familyName | Hirano |
142 | ″ | schema:givenName | Tsutomu |
143 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016274235662.39 |
144 | ″ | rdf:type | schema:Person |
145 | sg:person.0732262025.70 | schema:affiliation | grid-institutes:grid.417368.f |
146 | ″ | schema:familyName | Michishita |
147 | ″ | schema:givenName | Ichiro |
148 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732262025.70 |
149 | ″ | rdf:type | schema:Person |
150 | sg:person.0751577337.13 | schema:affiliation | grid-institutes:grid.410848.1 |
151 | ″ | schema:familyName | Iwasaki |
152 | ″ | schema:givenName | Tadao |
153 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751577337.13 |
154 | ″ | rdf:type | schema:Person |
155 | sg:pub.10.1007/s40618-016-0433-9 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1052469678 |
156 | ″ | ″ | https://doi.org/10.1007/s40618-016-0433-9 |
157 | ″ | rdf:type | schema:CreativeWork |
158 | grid-institutes:grid.410714.7 | schema:alternateName | Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan |
159 | ″ | schema:name | Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, Tokyo, Japan |
160 | ″ | rdf:type | schema:Organization |
161 | grid-institutes:grid.410848.1 | schema:alternateName | Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan |
162 | ″ | schema:name | Advanced Medical Technology and Development Division, BML Inc., Kawagoe, Japan |
163 | ″ | rdf:type | schema:Organization |
164 | grid-institutes:grid.417368.f | schema:alternateName | Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan |
165 | ″ | schema:name | Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, 132 Katsura-cho, Sakae-ku, 247-8581, Yokohama, Japan |
166 | ″ | rdf:type | schema:Organization |